This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barrans, S. L. Articles by Jack, A. S. Search for Related Content PubMed PubMed Citation Articles by Barrans, S. L. Articles by Jack, A. S.

The t(14;18) Is Associated with Germinal Center-derived Diffuse Large B-Cell Lymphoma and Is a Strong Predictor of Outcome¹

HMDS, Academic Unit of Haematology and Oncology, Leeds General Infirmary, Leeds LS1 3EX [S. L. B., P. A. S. E., S. J. M. O., S. J. K., R. G. O., G. J. M., A. S. J.], and Department of Haematology, Nottingham City Hospital, Nottingham [A. P. H.], United Kingdom

The t(14;18) is present in a significant proportion of diffuse large B-cell lymphomas (DLBCLs), however, the prognostic effect of the translocation and the relationship with transformed follicular lymphoma remains controversial.

To clarify these uncertainties, interphase fluorescence in situ hybridization (FISH) was used to determine the incidence of the t(14;18) in nodal DLBCL, and this was correlated with BCL2 expression, germinal center (GC) immunophenotype, and patient outcome. FISH was performed on paraffin-extracted nuclei from 137 de novo nodal DLBCLs.

Eighteen of 137 de novo DLBCLs were t(14;18) positive. The t(14;18) was most commonly associated with the subset of DLBCLs that expressed a GC phenotype, defined as CD10+, BCL6+ (GC-type DLBCL): positive in 14 of 47 (30%) cases, compared with 4 of 89 (5%) in the non-GC group (Pearson’s ² = 28.4; P < 0.0001). All cases with a translocation expressed BCL2 protein, however, 40 expressed BCL2 protein without a t(14;18). GC-type DLBCL patients with a t(14;18) had a significantly worse survival compared with GC-type DLBCL patients without the translocation (2-year survivals were 29 and 63%, respectively; P = 0.006). Of the cases without the translocation, BCL2 protein expression did not affect survival. In contrast, in the non-GC group of DLBCLs, BCL2 protein expression reduced the 2-year overall survival from 64% in the BCL2-negative group to 38%, with a median survival of 15.0 months (P = 0.02).

In conclusion, the t(14;18) is common in DLBCLs, particularly in GC-type DLBCLs, where the presence of the translocation has a poor prognostic effect. BCL2 protein expression defines a group of non-GC DLBCL patients with a poor prognosis.

This article has been cited by other articles:

				J. Dierlamm, E. M. Murga Penas, S. Bentink, S. Wessendorf, H. Berger, M. Hummel, W. Klapper, D. Lenze, A. Rosenwald, E. Haralambieva, et al. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma Haematologica, May 1, 2008; 93(5): 688 - 696. [Abstract] [Full Text] [PDF]

				P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2 Ann. Onc., March 1, 2008; 19(3): 560 - 565. [Abstract] [Full Text] [PDF]

				M. Pilichowska, S. Klepper, G. Campbell, A. Klein, A. Ernst, and G. Finlay A 64-Year-Old Woman With Cough and Right Middle Lobe Collapse Chest, November 1, 2007; 132(5): 1691 - 1696. [Full Text] [PDF]

				G. Mattsson, S. Y. Tan, D. J.P. Ferguson, W. Erber, S. H. Turner, T. Marafioti, and D. Y. Mason Detection of Genetic Alterations by ImmunoFISH Analysis of Whole Cells Extracted from Routine Biopsy Material J. Mol. Diagn., September 1, 2007; 9(4): 479 - 489. [Abstract] [Full Text] [PDF]

				G. W. van Imhoff, E.-J. G. Boerma, B. van der Holt, E. Schuuring, L. F. Verdonck, H. C. Kluin-Nelemans, and P. M. Kluin Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 1, 2006; 24(25): 4135 - 4142. [Abstract] [Full Text] [PDF]

				J. Iqbal, V. T. Neppalli, G. Wright, B. J. Dave, D. E. Horsman, A. Rosenwald, J. Lynch, C. P. Hans, D. D. Weisenburger, T. C. Greiner, et al. BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 961 - 968. [Abstract] [Full Text] [PDF]

				P. De Paepe, R. Achten, G. Verhoef, I. Wlodarska, M. Stul, V. Vanhentenrijk, M. Praet, and C. De Wolf-Peeters Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas J. Clin. Oncol., October 1, 2005; 23(28): 7060 - 7068. [Abstract] [Full Text] [PDF]

				I. S. Lossos Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6351 - 6357. [Abstract] [Full Text] [PDF]